Prognostic Determinants in Patients With Stage I Uterine Papillary Serous Carcinoma A 15-Year Multi-Institutional Review

被引:24
|
作者
Growdon, Whitfield B. [1 ]
Rauh-Hain, J. Jose A. [1 ,2 ]
Cordon, Adriana [1 ]
Garrett, Leslie [1 ]
Schorge, John O. [1 ]
Goodman, Annekathryn [1 ]
Boruta, David M. [1 ]
Horowitz, Neil S. [2 ]
del Carmen, Marcela G. [1 ]
机构
[1] Massachusetts Gen Hosp, Div Gynecol Oncol Vincent Obstet & Gynecol, Boston, MA 02114 USA
[2] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Gynecol Oncol, Boston, MA 02115 USA
关键词
Uterine papillary serous cancer; Stage; Endometrial cancer; Surgery; CLEAR-CELL CARCINOMA; PHASE-II; ENDOMETRIAL CARCINOMA; CHEMOTHERAPY; SURVIVAL; RADIOTHERAPY; OUTCOMES; BRACHYTHERAPY; PATTERNS; THERAPY;
D O I
10.1097/IGC.0b013e31823c6e36
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: The aim of this retrospective, multi-institutional study was to evaluate the importance of surgical staging for stage I uterine papillary serous carcinomas (UPSCs) to determine optimal management of this rare tumor. Methods: With institutional review board approval from both participating institutions, all patients with 2009 International Federation of Gynecology and Obstetrics stage I mixed serous and UPSC diagnosed between January 1, 1992, and December 31, 2007, were identified at the 2 institutions. Clinical factors were correlated using Spearman correlation coefficients, Kaplan-Meier survival estimates and a Cox proportional hazards model. Results: Of the 204 UPSC patients treated during this period, 84 were classified as stage I, with substages as follows: stage IA, n = 71; stage IB, n = 13. Thirty-seven patients (44%) had a history of a second cancer (22 breast tumors, 9 synchronous mullerian cancers). Surgical staging with at least hysterectomy, bilateral salpingo-oophorectomy, omentectomy, and bilateral pelvic lymph node dissection was performed in 60 (71%) of 84 patients. The median survival for all patients was 10 years. Univariate analysis revealed surgical staging (P < 0.001), normal preoperative CA-125 (P < 0.001), and absence of additional cancers (P < 0.01) to be associated with improved survival. Age-adjusted multivariate analysis incorporating these factors revealed that advancing substage (hazard ratio, 4.59; P < 0.05), a second malignancy (hazard ratio, 2.75; P < 0.04), and surgical staging (hazard ratio, 0.18; P G 0.001) were independent factors associated with overall survival. In a subset analysis excluding patients with a second malignancy, substage (hazard ratio, 3.52; P < 0.05), and surgical staging (hazard ratio, 0.16; P < 0.001) were independent factors affecting overall survival. Conclusions: Independent of adjuvant chemotherapy or radiation, stage of disease, comprehensive surgical staging, and the presence of a second malignancy were predictors of overall survival.
引用
收藏
页码:417 / 424
页数:8
相关论文
共 50 条
  • [1] Prognostic determinants in patients with stage IIIC and IV uterine papillary serous carcinoma
    Rauh-Hain, J. Alejandro
    Growdon, Whitfield B.
    Schorge, John O.
    Goodman, A. K.
    Boruta, David M.
    McCann, Christopher
    Horowitz, Neil S.
    del Carmen, Marcela G.
    GYNECOLOGIC ONCOLOGY, 2010, 119 (02) : 299 - 304
  • [2] Tumor Size as a Prognostic Factor in Uterine Serous Carcinoma: A Large Multi-Institutional Study
    Bandyopadhyay, S.
    Van de Vijver, K. K.
    Oliva, E.
    Nucci, M. R.
    Shi, D.
    Qureshi, F.
    Hayek, K.
    Alosh, B.
    Feng, Z.
    Jaratli, H.
    Schultz, D.
    Ali-Fehmi, R.
    LABORATORY INVESTIGATION, 2012, 92 : 259A - 259A
  • [3] Tumor Size as a Prognostic Factor in Uterine Serous Carcinoma: A Large Multi-Institutional Study
    Bandyopadhyay, S.
    Van de Vijver, K. K.
    Oliva, E.
    Nucci, M. R.
    Shi, D.
    Qureshi, F.
    Hayek, K.
    Alosh, B.
    Feng, Z.
    Jaratli, H.
    Schultz, D.
    Ali-Fehmi, R.
    MODERN PATHOLOGY, 2012, 25 : 259A - 259A
  • [4] Adjuvant therapy in women with early stage uterine serous carcinoma: A multi-institutional study
    Kurnit, Katherine C.
    Nobre, Silvana Pedra
    Fellman, Bryan M.
    Iglesias, David A.
    Lindemann, Kristina
    Jhingran, Anuja
    Eriksson, Ane Gerda Z.
    Ataseven, Beyhan
    Glaser, Gretchen E.
    Mueller, Jennifer J.
    Westin, Shannon N.
    Soliman, Pamela T.
    GYNECOLOGIC ONCOLOGY, 2022, 167 (03) : 452 - 457
  • [5] Adjuvant vaginal brachytherapy decreases the risk of vaginal recurrence in patients with stage I non-invasive uterine papillary serous carcinoma. A multi-institutional study
    Mandi, Haider
    Rose, Peter G.
    Elshaikh, Mohammed A.
    Munkarah, Adnan
    Isrow, Derek
    Singh, Sareena
    Waggoner, Steven
    Ali-Fehmi, Rouba
    Morris, Robort T.
    Harding, Jarod
    DeBenardo, Robert
    GYNECOLOGIC ONCOLOGY, 2015, 136 (03) : 529 - 533
  • [6] Outcomes in surgical stage I uterine papillary serous carcinoma
    Havrilesky, Laura J.
    Secord, Angeles Alvarez
    Bae-Jump, Victoria
    Ayeni, Tina
    Calingaert, Brian
    Clarke-Pearson, Daniel L.
    Berchuck, Andrew
    Gehrig, Paola A.
    GYNECOLOGIC ONCOLOGY, 2007, 105 (03) : 677 - 682
  • [7] Correlation of tumor size with other prognostic factors in uterine serous carcinoma: A large multi-institutional study
    Winer, I.
    Mahdi, H.
    Bandyopadhyay, S.
    Semaan, A.
    Van de Vijver, K. K.
    Nucci, M. R.
    Abdul-Karim, F.
    Hussein, Y.
    Qureshi, F.
    Hayek, K.
    Alosh, B.
    Schulz, D.
    Cote, M.
    Munkarah, A.
    Morris, R.
    Oliva, E.
    Ali-Fehmi, R.
    GYNECOLOGIC ONCOLOGY, 2013, 128 (02) : 316 - 321
  • [8] TREATMENT AND OUTCOMES OF STAGE I UTERINE PAPILLARY SEROUS CARCINOMA IN BRITISH COLUMBIA
    van der Putten, L. J. M.
    Hoskins, P. J.
    Tinker, A. V.
    Lim, P.
    Parsons, C.
    Kwon, J. S.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2013, 23 (08)
  • [9] Treatment of stage I seminoma: A 15-year review
    Alomary, I
    Samant, R
    Gallant, V
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2006, 24 (03) : 180 - 183
  • [10] Epidemiology of Pediatric Heart Failure in the USA–a 15-Year Multi-Institutional Study
    Raysa Morales-Demori
    Elena Montañes
    Gwen Erkonen
    Michael Chance
    Marc Anders
    Susan Denfield
    Pediatric Cardiology, 2021, 42 : 1297 - 1307